Importance of Age-Specific Insurer Perspective on Lifetime Cost Effectiveness of Colorectal Cancer Screening.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30374119.
- Also identified by DOI 10.1038/s41395-018-0386-z and PMC identifier 6768587.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In "Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer (CRC) Screening under Commercial Insurance vs. Medicare", Ladabaum et al. model different CRC screening scenarios that vary the combination of payer, perspective, screening ages, and time horizons. Fecal occult blood testing (FOBT), fecal immunochemical testing (FIT), colonoscopy and flexible sigmoidoscopy were all cost effective compared to no screening, even if initiating or stopping at age 65 years. Assuming perfect adherence, FIT and FOBT were cost saving and dominated colonoscopy. Screening between ages 50 and 64 years appeared relatively costly if only a limited time horizon was considered since the benefits accrue after age 65 years under Medicare.
Medical subject headings
- Colorectal Neoplasms
- Early Detection of Cancer